For example, the CAR-HEMATOTOX Score enables risk assessment for hematologic toxicity, severe infection, and disease progression following anti-CD19 CAR T cell therapy in refractory/relapsed large B-cell lymphoma (R/R LBCL)17,18, and also holds prognostic value for response and toxicity in MM patients treated with BCMA-directed CAR T cells19. This evidence concerns the gene CD19 and Miyoshi myopathy.